Literature DB >> 15671048

Dramatic improvement with anakinra in a case of chronic infantile neurological cutaneous and articular (CINCA) syndrome.

B Granel, J Serratrice, P Disdier, P-J Weiller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15671048     DOI： 10.1093/rheumatology/keh547

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  12 in total

1.  Anakinra in mutation-negative CINCA syndrome.

Authors:  José Luis Callejas; Javier Oliver; Javier Martín; Norberto Ortego
Journal:  Clin Rheumatol       Date:  2006-01-27       Impact factor: 2.980

2.  Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome.

Authors:  S C B Teoh; S Sharma; A Hogan; R Lee; A V Ramanan; A D Dick
Journal:  Br J Ophthalmol       Date:  2007-02       Impact factor: 4.638

Review 3.  The PYRIN domain in signal transduction.

Authors:  Christian Stehlik
Journal:  Curr Protein Pept Sci       Date:  2007-06       Impact factor: 3.272

Review 4.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

5.  Extreme efficiency of anti-interleukin 1 agent (anakinra) in a Japanese case of CINCA syndrome.

Authors:  Yasuyo Kashiwagi; Hisashi Kawashima; Shigeo Nishimata; Ryuhei Nagao; Kiyoko Watanabe; Kouji Takekuma; Akinori Hoshika
Journal:  Clin Rheumatol       Date:  2007-09-22       Impact factor: 2.980

Review 6.  Unleashing the therapeutic potential of NOD-like receptors.

Authors:  Kaoru Geddes; João G Magalhães; Stephen E Girardin
Journal:  Nat Rev Drug Discov       Date:  2009-06       Impact factor: 84.694

7.  Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome.

Authors:  Donato Rigante; Valentina Ansuini; Barbara Bertoni; Anna Lisa Pugliese; Laura Avallone; Gilda Federico; Achille Stabile
Journal:  Rheumatol Int       Date:  2006-07-27       Impact factor: 2.631

8.  An inflammasome-independent role for epithelial-expressed Nlrp3 in renal ischemia-reperfusion injury.

Authors:  Alana A Shigeoka; James L Mueller; Amanpreet Kambo; John C Mathison; Andrew J King; Wesley F Hall; Jean da Silva Correia; Richard J Ulevitch; Hal M Hoffman; Dianne B McKay
Journal:  J Immunol       Date:  2010-10-20       Impact factor: 5.422

Review 9.  Biologics in children's autoimmune disorders: efficacy and safety.

Authors:  Luciana Breda; Marianna Del Torto; Sara De Sanctis; Francesco Chiarelli
Journal:  Eur J Pediatr       Date:  2010-06-17       Impact factor: 3.183

10.  Hydrocephalus in CINCA syndrome treated with anakinra.

Authors:  D Rigante; V Ansuini; M Caldarelli; B Bertoni; I La Torraca; A Stabile
Journal:  Childs Nerv Syst       Date:  2006-03-09       Impact factor: 1.475
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.